Advanced Search

 

Study ID Status Title Patient Level Data
102247/036 Completed A multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines Study Listed on ClinicalStudyDataRequest.com
102247/036 Annex Completed A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines
102248 Completed Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants Study Listed on ClinicalStudyDataRequest.com
102370 (primary study) Completed A multicentre primary & booster vaccination study of GSK Biologicals' Hib-MenCY-TT conjugate vaccine vs ActHIB® & MenC conjugate licensed vaccine when given according to the 2-4-6 month schedule to healthy infants with booster dose at 12 to 15 months Study Listed on ClinicalStudyDataRequest.com
102394 Completed A Phase IV, partially double-blind study to demonstrate non-inferiority of GSK Biologicals’ Mencevax™ ACWY (new process) versus Mencevax™ ACWY (current process) when administered as a single dose to subjects aged 2-30 yrs Study Listed on ClinicalStudyDataRequest.com
102499 Completed A phase III, open, randomized, multicenter, comparative vaccination study to evaluate the immunogenicity and reactogenicity of various formulations of a monovalent candidate pandemic influenza A vaccine in individuals over 60 years of age Study Listed on ClinicalStudyDataRequest.com
102547 Completed Evaluate immunogenicity,safety & reactogenicity of a booster dose of Hib-MenC conjugate vaccine when given to healthy subjects aged 13-14 months who were primed with 3 doses of Hib-MenC vs a booster dose of Infanrix hexa given to subjects primed with 3 doses of Infanrix hexa and Meningitec Study Listed on ClinicalStudyDataRequest.com
102587 Completed A Single-Dose, Open-Label, Randomized, Three-Way Cross-Over Study in Healthy Subjects to Evaluate the Relative Bioequivalence of Two New Small Tablet Formulations of Lapatinib (GW572016)
102761 Completed An Open-Label Randomized Study with 3 Cohorts of 3-Way Crossovers to Investigate the Safety Tolerability and Pharmacokinetics of 45mg Oral Doses of GW823093C and 500mg BID Oral Doses of Metformin (Cohort 1) 8mg Oral Doses of Rosiglitazone (Cohort 2) and 45mg Oral Doses of Pioglitazone (Cohort 3) Study Listed on ClinicalStudyDataRequest.com
102860 Completed A Two-Part, Randomized, Placebo-Controlled Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Single, Oral Doses of the Thrombopoietin Receptor Agonist, Eltrombopag; and the Effect of Eltrombopag on Cardiac Repolarization as Compared to Placebo and Single Oral Doses of Moxifloxacin in Healthy Adult Subjects
102861 Completed An Open-Label Mass Balance Study to Investigate the Metabolic Disposition of a Single Oral Dose of 14C SB-497115-GR in Healthy Male Subjects.
102863 Completed A randomized, open-label, two-period, period-balanced, crossover study with three parallel groups to evaluate the relative bioavailability of single oral doses of SB-497115-GR (eltrombopag) phase III tablets [50 mg, 75 mg, 100 mg] compared to SB-497115-GR phase II tablets [25mg and 50 mg] in healthy
102871 Completed HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
102886/003 Completed Safety, tolerance and preliminary pharmacokinetics of single ascending intravenous doses of halofantrine [SK&F 102886] in healthy male volunteers.
102886/034 Completed An Open Study on the Tolerance, Safety and Pharmacokinetics of Halofantrine Hydrochloride 500mg in Single Administration in Healthy Adult Volunteers
102932 Completed An open-label, randomised, 3-way crossover single dose study to demonstrate dose proportionality of fluticasone furoate (FF) and equivalence of vilanterol (VI) when administered as FF/VI inhalation powder from the novel dry powder inhaler in healthy subjects. Study Listed on ClinicalStudyDataRequest.com
102934 Completed An open-label, non-randomised, three-way crossover, single dose study to determine the absolute bioavailability of fluticasone furoate (FF)/GW642444 Inhalation Powder, in healthy subjects Study Listed on ClinicalStudyDataRequest.com
102936 Completed A randomised, placebo-controlled, four-way crossover repeat dose study to evaluate the effect of the inhaled fluticasone furoate (FF)/GW642444M combination on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects Study Listed on ClinicalStudyDataRequest.com
102970 Completed HZC102970: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
103078 Completed An open, randomised, crossover study to assess the pharmacokinetics and tolerability of single doses of LAPDAP™, artesunate, and LAPDAP plus artesunate Study Listed on ClinicalStudyDataRequest.com
103094 Completed ARI103094-Follow-Up Study for REDUCE Study Subjects Study Listed on ClinicalStudyDataRequest.com
103096 Completed A randomised, double blind, placebo controlled, incomplete block, five-way cross-over study to investigate the effect of one week repeat dosing of GW685698X and inhaled fluticasone propionate (FP) on twenty-four hour serum cortisol in healthy subjects. Study Listed on ClinicalStudyDataRequest.com
103106 Completed An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
103367 Completed A single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers
103369 Completed A randomized phase III study of cisplatin versus cisplatin plus topotecan versus methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) in stage IVB, recurrent or persistent carcinoma of the cervix.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.